Concepedia

First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

Bruce Hughes, Mark Cascione, Mark S. Freedman, Mark Agius, Daniel Kantor, Mark Gudesblatt, Lawrence Goldstick, Neetu Agashivala, Lesley Schofield, Ron Hashmonay,

Multiple Sclerosis and Related Disorders · 2014 · 13 citations · 9 references

DOI

Concepts

References

9

Rating neurologic impairment in multiple sclerosis

John F. Kurtzke · Neurology · 1983 · 14.9K citations

, , +14

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

Ludwig Kappos, Ernst‐Wilhelm Radue, Paul O’Connor et al. · New England Journal of Medicine · 2010 · 2.6K citations · Full text

, , +14

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

Jeffrey A. Cohen, Frederik Barkhof, Hans‐Peter Hartung et al. · New England Journal of Medicine · 2010 · 2.2K citations · Full text

, , +15

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

Ludwig Kappos, Jack P. Antel, Giancarlo Comi et al. · New England Journal of Medicine · 2006 · 1.1K citations · Full text

, , +8

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Peter A. Calabresi, Ernst-Wilhelm Radüe, Douglas S. Goodin et al. · The Lancet Neurology · 2014 · 822 citations

, , +7